The deal gains BioMarin a novel oral therapy for HPP, potentially expanding into a larger rare disease market. The all-cash structure and expected Q3 close limit balance-sheet risk. Watch for the closing, any regulatory updates on ALE-1, and updated 2026 guidance. The spin-out structure means no employee integration risk.
BMRN drugs
BMRN drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 18 $66.99entry
- T+1 · 3mo ago +3.49%α +3.28% · $69.33
- T+5 · 3mo ago −1.30%α −1.10% · $66.12
- T+20 · 2mo ago −3.25%α −2.26% · $64.81
- T+60 · 6d ago −14.72%α −12.68% · $57.13
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
BioMarin (BMRN) entered into a definitive Share Purchase Agreement to acquire Alesta Therapeutics for $275 million upfront in cash, with up to $215 million in additional milestone-based payments, for a total potential consideration of up to $490 million. Alesta's lead asset is ALE-1, an oral small-molecule in a Phase 1/2a trial for hypophosphatasia (HPP). The deal is expected to close in Q3 2026, funded from cash on hand.
Key Financial Metrics
Key Facts
- BioMarin to acquire Alesta Therapeutics for $275M upfront cash, subject to customary post-closing purchase price adjustment.
- Up to $215M in additional milestone payments tied to development and regulatory achievements for ALE-1.
- ALE-1 is an orally active small molecule in Phase 1/2a for hypophosphatasia (HPP), a rare genetic bone disease with over 9,000 diagnosed patients in the US.
- Alesta will spin out all non-ALE1 assets to a new entity (Anaheim SpinCo) prior to closing; no Alesta employees will join BioMarin.
- Transaction expected to close in Q3 2026, funded with BioMarin's cash on hand.
- Excluding the upfront consideration, the deal is expected to be modestly dilutive to 2026 financial results.
- BioMarin plans to update full-year 2026 guidance after closing.
Financial Impact
Up to $490 million total potential consideration ($275M upfront + up to $215M milestones), all in cash. BioMarin intends to use cash on hand.
Risk Factors
- Clinical and regulatory uncertainty: ALE-1 is still in Phase 1/2a; failure or delay would impair milestone value.
- Milestone payments are contingent on future events; if milestones are not achieved, total consideration will be lower.
- The spin-out of non-ALE1 assets must be completed before close; any complication could delay closing.
- The upfront $275M outlay will reduce cash reserves, and the deal is expected to be modestly dilutive to 2026 EPS.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-354780 |
| Document: d172628d8k.htm | 0001193125-26-354780 |
| Document: d172628dex991.htm | 0001193125-26-354780 |
| Document: 0001193125-26-354780-index-headers.html | 0001193125-26-354780 |
| Document: 0001193125-26-354780-index.html | 0001193125-26-354780 |
| Document: 0001193125-26-354780.txt | 0001193125-26-354780 |
Track record
16 reports on BMRN
2 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +8.91% at T+60 after the Apr 27, 2026 report. 2 of 4 went positive at some point.
Filters
- Nov 4, 202612d ago SC 13G/A Neutral 3/10 Entry $56.12 to $56.70 Now $57.99 +3.33% ▲ +1.03% −2.26% vs SPY
- Nov 2, 202614d ago 8-K Bearish 6/10 Entry $55.66 to $57.13 Now $57.99 −4.19% ▼ −2.64% −3.23% vs SPY
- Oct 29, 202618d ago Institutional Cluster Neutral 2/10 Entry $57.49 to $56.12 Now $57.99 +0.87% ▼ −2.38% +2.34% vs SPY
- Oct 27, 202620d ago Institutional Cluster Mixed 3/10 Entry $56.00 to $57.13 Now $57.99 +3.55% ▲ +2.02% +2.73% vs SPY
- Oct 6, 20265w ago 8-K Bearish 6/10 Entry $55.20 to $55.14 Now $57.99 −5.05% ▲ +0.11% −0.87% vs SPY
- Sep 15, 20268w ago 8-K Neutral 4/10 Entry $64.45 to $63.94 Now $57.99 −10.02% ▼ −0.79% −1.61% vs SPY
- Sep 14, 20269w ago 8-K Neutral 2/10 Entry $66.41 to $64.06 Now $57.99 −12.68% ▼ −3.54% −3.65% vs SPY
- Sep 1, 202610w ago 8-K Neutral 3/10 Entry $64.84 to $64.41 Now $57.99 −10.56% ▼ −0.66% −0.74% vs SPY
- Sep 1, 202610w ago Press Release Neutral 4/10 Entry $64.84 to $64.41 Now $57.99 −10.56% ▼ −0.66% −0.74% vs SPY
- Aug 31, 202611w ago 8-K Bullish 6/10 Entry $65.23 to $64.63 Now $57.99 −11.10% ▼ −0.92% −0.78% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers